TO-O-1001 / Metagone Biotech - LARVOL DELTA

A report of a newly developed rho kinase inhibitor (TO-O-1001) on human phase one and two trials (ARVO 2024) - P1/2 | "Current safety and the IOP-lowing effect of TO-O-1001 in patients appear comparable, potentially even better, with those published results of the marketed ROCKi. Therefore, TO-O-1001 presents a potential option for patients with OAG, with more profound IOP reduction effect and better safety and tolerability profiles."

Glaucoma • Ophthalmology

A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2 | N=50 | Active, not recruiting | Sponsor: Theratocular Biotek Co. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Jul 2023 ➔ Jul 2024 | Trial primary completion date: Mar 2023 ➔ Dec 2023

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Theratocular Biotek Co.

New P1/2 trial • Cardiovascular • Glaucoma • Ophthalmology